Agios Pharmaceuticals, Inc. Forecast, price target & analysts
Agios Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Agios Pharmaceuticals, Inc. Classifications & Recommendation:
Agios Pharmaceuticals, Inc. Price Target
| Target Price | $32.64 |
| Price | $29.17 |
| Potential |
11.90%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2026 .
The average Agios Pharmaceuticals, Inc. target price is $32.64.
This is
11.90%
register free of charge
$50.40
72.78%
register free of charge
$20.20
30.75%
register free of charge
|
|
| A rating was issued by 16 analysts: 12 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2026 of
11.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.50 | 46.99 |
| 36.09% | 28.74% | |
| EBITDA Margin | -1,150.90% | -1,025.23% |
| 19.80% | 10.92% | |
| Net Margin | 1,845.84% | -893.03% |
| 240.60% | 148.38% |
12 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2025 . The average Agios Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2025. The average Agios Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Agios Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 11.64 | -7.20 |
| 283.89% | 161.86% | |
| P/E | negative | |
| EV/Sales | 15.92 |
12 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Agios Pharmaceuticals, Inc....
Current Agios Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 26 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 26 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 20 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Nov 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Nov 20 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
